USPTO serial 79385808
INVENTIA
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- Jan 20, 2026
- Examiner
- YOUNG, CARRIE SKYE
- Law office
- Historical data usage
What this means
Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six. Calendar Section 8 between years five and six, and consider trademark monitoring.
Need help with INVENTIA?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Robyn S. Lederman
Robyn S. Lederman Brooks Kushman PC150 Second Ave, Suite 400NCorner Hunter and Phillip StreetsRoyal Oak, MI 48067Goods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 007 | 3D printers; computerized printers for the generation of 3D shaped parts; machines, namely, 3D bioprinters for the printing of living cells and tissues or printing 3D cell structures; cartridges being parts of 3D printers for containing printing materials; cartridges being parts of 3D printers for containing bioprinting materials; printing cartridges being parts of 3D printers for containing biomaterials and reagents; printing cartridges being parts of 3D printers for containing bio-ink; robotic handling apparatus, namely, robotic handling apparatus and arms for industrial and commercial use; accessories and spare parts for three dimensional (3D) printers for the production of biological materials, namely, print heads for three dimensional (3D) printers; machines, namely, three dimensional (3D) printer for the printing of engineered living tissues; three dimensional (3D) printers; structural parts and fittings therefor * ; none of the foregoing being in relation to oral or injectable therapies for the treatment of patient needs in the areas of fibrosis, lysosomal storage disorders and oncology, cardiometabolic diseases, liver diseases, metabolic disorders (including obesity, diabetes, severe dyslipidemias, NASH), inflammatory diseases and autoimmune diseases * | ACTIVE | — |
| 009 | Laboratory robots; downloadable software for monitoring and controlling communication between computers and automated machine systems; downloadable software for operating and controlling 3D printers; downloadable operating software to control laboratory apparatus for fabrication of three dimensional (3D) engineered living tissues; downloadable software for the purpose of the manufacture of products by means of a 3D printer, including medical products; laboratory instruments and apparatus, namely, cell assembly apparatus for laboratory use for fabrication of three dimensional (3D) engineered living tissues; print heads for 3D printers and bioprinters; downloadable electronic publications, namely, pamphlets, brochures, journals, books, manuals, newsletters and booklets in the field of living tissue, tissue regeneration, 3D printing, cell printing, cell assembly and biomedical research; parts and fittings for all of the foregoing, namely, electronic control panels with digital displays for the control of three dimensional (3D) printers, printer cables, and ink cartridges, unfilled, for printers * ; none of the foregoing being in relation to oral or injectable therapies for the treatment of patient needs in the areas of fibrosis, lysosomal storage disorders and oncology, cardiometabolic diseases, liver diseases, metabolic disorders (including obesity, diabetes, severe dyslipidemias, NASH), inflammatory diseases and autoimmune diseases * | ACTIVE | — |
| 010 | Surgical robots, namely, robotic apparatus for medical or surgical purposes; surgical robots; surgical robots for medical purposes; medical apparatus for use in soft tissue repair, reconstruction of soft tissue deficiencies, regenerative surgery, plastic reconstructive surgery and wound healing in the field of living tissue, tissue regeneration, 3D printing, bioprinting, cell printing, cell assembly and biomedical research; structural parts and fittings therefor; none of the foregoing being in relation to oral or injectable therapies for the treatment of patient needs in the areas of fibrosis, lysosomal storage disorders and oncology, cardiometabolic diseases, liver diseases, metabolic disorders, obesity, diabetes, severe dyslipidemias, NASH, inflammatory diseases and autoimmune diseases | ACTIVE | — |
| 035 | Data management; wholesale and retail store services for pharmaceutical, medical, scientific, laboratory and 3D printing consumables and supplies; online wholesale and retail store services featuring pharmaceutical, medical, scientific, laboratory and 3D printing consumables and supplies; administrative processing of purchase orders; order fulfillment services, namely, computerised stock ordering and purchasing; computerised data processing; compiling and analyzing statistics, data and other sources of scientific information for business purposes; computerised register management, namely, maintenance of registers for others * none of the foregoing being in relation to oral or injectable therapies for the treatment of patient needs in the areas of fibrosis, lysosomal storage disorders and oncology, cardiometabolic diseases, liver diseases, metabolic disorders (including obesity, diabetes, severe dyslipidemias, NASH), inflammatory diseases and autoimmune diseases * | ACTIVE | — |
| 042 | Scientific and technological services and research and design relating thereto, all in the field of living tissue, tissue regeneration, 3D printing, bioprinting, cell printing, cell assembly and biomedical research; industrial analysis, industrial research and industrial design services, all in the field of living tissue, tissue regeneration, 3D printing, bioprinting, cell printing, cell assembly and biomedical research; design and development of computer software; software as a service (SAAS) services, namely, hosting software for use by others in the field of living tissue, tissue regeneration, 3D printing, bioprinting, cell printing, cell assembly and biomedical research and to identify, select and print biomaterials for the purpose of experiments; providing online non-downloadable software for use by others in the field of living tissue, tissue regeneration, 3D printing, bioprinting, cell printing, cell assembly and biomedical research and to identify, select and print biomaterials for the purpose of experiments; computer support services, namely, computer programming and software installation, repair and maintenance services; scientific research services, specifically, analysis of statistical data for scientific research purposes; design of software; design and development of new products in the field of biological materials; visual design services in the nature of designing visual elements for print media; new product design services; scientific research relating to design in the field of 3D printing, bioprinting, cell printing, cell assembly and biomedical research; laboratory research in the field of biomedical research, bioprinting, cell printing, cell assembly and the creation and engineering of 3D cells and living tissues; biomedical research; cloud computing featuring software for use in the field of living tissue, tissue regeneration, 3D printing, bioprinting, cell printing, cell assembly and biomedical research and to identify, select and print biomaterials for the purpose of experiments; technical consultancy in the field of scientific research; scientific research in the field of soft tissue repair, reconstruction of soft tissue deficiencies, regenerative surgery, plastic reconstructive surgery, wound healing, drug discovery, genetics, dermatology and oncology; scientific research into the development of new products; technical support services, namely, troubleshooting in the nature of repair of medical equipment and diagnostic laboratory instruments and systems; providing online non-downloadable web-based computer software platforms for laboratory and diagnostic equipment information management, monitoring and analysis; providing information and online information regarding the foregoing; none of the foregoing being in relation to oral or injectable therapies for the treatment of patient needs in the areas of fibrosis, lysosomal storage disorders and oncology, cardiometabolic diseases, liver diseases, metabolic disorders (including obesity, diabetes, severe dyslipidemias, NASH), inflammatory diseases and autoimmune diseases | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by Inventia Pty Ltd
- Other trademarks owned by Inventia Pty Ltd
- Other trademarks owned by Inventia Pty Ltd
- Other trademarks in Class 007
- Other trademarks in Class 009
- Other trademarks in Class 010
- Other trademarks in Class 035
- Other trademarks in Class 042
- Similar marks named INVENTIA
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Sep 3, 2026 | FINO | FINAL DECISION TRANSACTION PROCESSED BY IB | — |
| Aug 20, 2026 | NREP | NEW REPRESENTATIVE AT IB RECEIVED | — |
| Jul 23, 2026 | FICS | FINAL DISPOSITION NOTICE SENT TO IB | — |
| Jul 23, 2026 | FIMP | FINAL DISPOSITION PROCESSED | — |
| Jul 7, 2026 | NURC | NOTICE OF UPDATED REGISTRATION CONFIRMATION EMAILED | — |
| Jun 17, 2026 | LIME | LIMITATION FROM THE IB EXAMINED AND ENTERED | — |
| Jun 17, 2026 | COC. | CORRECTION UNDER SECTION 7 - PROCESSED | — |
| Jun 17, 2026 | APRE | CASE ASSIGNED TO POST REGISTRATION PARALEGAL | — |
| Apr 20, 2026 | FICR | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB | — |
| Jan 20, 2026 | NRCC | NOTICE OF REGISTRATION CONFIRMATION EMAILED | — |
| Jan 20, 2026 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Dec 25, 2025 | LIMG | LIMITATION OF GOODS RECEIVED FROM IB | — |
| Dec 11, 2025 | GPNX | NOTIFICATION PROCESSED BY IB | — |
| Dec 2, 2025 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Dec 2, 2025 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Nov 26, 2025 | OPNS | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | — |
| Nov 26, 2025 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Nov 25, 2025 | OP2R | NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB | — |
| Oct 31, 2025 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Oct 27, 2025 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Oct 27, 2025 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Oct 27, 2025 | ERFR | TEAS REQUEST FOR RECONSIDERATION RECEIVED | — |
| Jun 6, 2025 | OPNX | NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB | — |
| May 23, 2025 | LIMG | LIMITATION OF GOODS RECEIVED FROM IB | — |
| May 22, 2025 | GNFN | NOTIFICATION OF FINAL REFUSAL EMAILED | — |
| May 22, 2025 | GNFR | FINAL REFUSAL E-MAILED | A final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon. |
| May 22, 2025 | CNFR | FINAL REFUSAL WRITTEN | A final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon. |
| May 20, 2025 | OPNS | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | — |
| May 20, 2025 | OPNR | NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB | — |
| Apr 15, 2025 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Apr 15, 2025 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Apr 15, 2025 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Mar 28, 2025 | LIMG | LIMITATION OF GOODS RECEIVED FROM IB | — |
| Nov 23, 2024 | RFNT | REFUSAL PROCESSED BY IB | — |
| Nov 4, 2024 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| Nov 4, 2024 | RFRR | REFUSAL PROCESSED BY MPU | — |
| Oct 30, 2024 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Oct 29, 2024 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Oct 22, 2024 | RFWR | NON-FINAL ACTION (IB REFUSAL) WITHDRAWN FOR REVIEW | — |
| Aug 30, 2024 | NREP | NEW REPRESENTATIVE AT IB RECEIVED | — |
| Aug 23, 2024 | NREP | NEW REPRESENTATIVE AT IB RECEIVED | — |
| Mar 24, 2024 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Mar 23, 2024 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Mar 22, 2024 | DOCK | ASSIGNED TO EXAMINER | — |
| Dec 26, 2023 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Dec 22, 2023 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Dec 21, 2023 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |